[HTML][HTML] The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
C Patel, JML Brotherton, A Pillsbury… - …, 2018 - eurosurveillance.org
Background: A National human papilloma virus (HPV) Vaccination Programme for the
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …
prevention of HPV infection and associated disease using the quadrivalent HPV vaccine …
Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a …
Background Cervical screening and human papillomavirus (HPV) vaccination have been
implemented in most high-income countries; however, coverage is low in low-income and …
implemented in most high-income countries; however, coverage is low in low-income and …
[HTML][HTML] Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population
Abstract In 2020, the World Health Organization (WHO) launched a strategy to eliminate
cervical cancer as a public health problem. To support the strategy, the WHO published …
cervical cancer as a public health problem. To support the strategy, the WHO published …
[HTML][HTML] The projected timeframe until cervical cancer elimination in Australia: a modelling study
Summary Background In 2007, Australia was one of the first countries to introduce a national
human papillomavirus (HPV) vaccination programme, and it has since achieved high …
human papillomavirus (HPV) vaccination programme, and it has since achieved high …
[HTML][HTML] Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study
Background Funding for human papillomavirus (HPV) vaccination in Japan began in 2010
for girls aged 12–16 years, with three-dose coverage initially reaching more than 70%. On …
for girls aged 12–16 years, with three-dose coverage initially reaching more than 70%. On …
[HTML][HTML] Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
Introduction The World Health Organization (WHO) recommends that human papillomavirus
(HPV) vaccination programs are established to be cost-effective before implementation …
(HPV) vaccination programs are established to be cost-effective before implementation …
[图书][B] Health economics: an international perspective
Health Economics: An International Perspective is the only textbook to provide a truly
international, comparative treatment of health economics. Offering an analysis of health …
international, comparative treatment of health economics. Offering an analysis of health …
[HTML][HTML] Projected time to elimination of cervical cancer in the USA: a comparative modelling study
Summary Background In May, 2018, the Director-General of WHO issued a global call to
eliminate cervical cancer as a public health problem, which will involve ambitious screening …
eliminate cervical cancer as a public health problem, which will involve ambitious screening …
Impact of disruptions and recovery for established cervical screening programs across a range of high-income country program designs, using COVID-19 as an …
COVID-19 has disrupted cervical screening in several countries, due to a range of policy-,
health-service and participant-related factors. Using three well-established models of …
health-service and participant-related factors. Using three well-established models of …
[HTML][HTML] Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis
Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …
in women and men up to age 45 years in the United States. The cost-effectiveness of HPV …